Dimopoulos M, Tedeschi A, Trotman J, et al. Multinational, randomized phase 3 trial of ibrutinib-rituximab vs placebo-rituximab with Waldenström’s macroglobulinemia. EHA 2018, abstract S852.
Ruxolitinib bij intermediair-1 risico myelofibrose
dec 2017 | MPN, Stamceltransplantatie